DTx are dead - long live DTx!

Picture the scene. It's 2019. You're at a conference. All anyone can talk about is DTx. \r\n'It's the future of pharma' they cry. 'This will change medicine forever'. But after so much hype, promise and expectation, do DTx still have the same appeal? Was DTx ever a whole new branch of health? Or was it just a digital rebrand of what already existed?Regulation, red tape and reimbursement remain significant hurdles, but we know DTx can provide real value. So how can DTx providers prove that value to Big Pharma, investors and patients alike?